Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial

BJU International

Volumn 107, Issue 6, 2011, Pages 946-954

  Roehrborn, Claus G ^a   Barkin, Jack ^b   Siami, Paul ^c   Tubaro, Andrea ^d   Wilson, Timothy H ^e   Morrill, Betsy B ^e   Gagnier, R Paul ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Deaconess Clinic   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Benign prostatic hyperplasia; Combined drug therapy; Dutasteride; Surgery; Tamsulosin; Urinary retention

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

AGE; ARTICLE; BODY MASS; DISEASE COURSE; DISEASE SEVERITY; EJACULATION DISORDER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; ORGAN SIZE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROSTATE SURGERY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; URINE FLOW RATE; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINARY RETENTION;

EID: 79952584014     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10124.x     Document Type: Article

References (26)

1. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102: 981-6
2. Emberton M, Andriole GL, de la Rosette J et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267-73 (Pubitemid 36206514)
3. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58: 5-16 (Pubitemid 34007591)
4. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7 (Pubitemid 27327692)
5. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999; 162: 376-82 (Pubitemid 29434344)
6. Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005; 47: 494-8 (Pubitemid 40357896)
7. Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006; 176: 200-4
8. Choong S, Emberton M. Acute urinary retention. BJU Int 2000; 85: 186-201 (Pubitemid 30066110)
9. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998; 81: 712-20 (Pubitemid 28316636)
10. Desgrandchamps F, De La Taille A, Doublet JD. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 2006; 97: 727-33 (Pubitemid 43383504)
11. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-7 (Pubitemid 29479405)
12. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63 (Pubitemid 28114643)
13. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
14. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53 (Pubitemid 47036593)
15. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-95 (Pubitemid 39200858)
16. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734-41 (Pubitemid 43383505)
17. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJEAU. 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54 (Pubitemid 39345720)
18. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
19. Kaplan SA, McConnell JD, Roehrborn CG et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol 2006; 175: 217-21
20. Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21
21. Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31
22. Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28: 770-9 (Pubitemid 47499255)
23. Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-6 (Pubitemid 32728058)
24. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009; 182: S27-31
25. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
26. Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80 (Pubitemid 29136187)